BioDelivery Sciences International (NASDAQ:BDSI) Raised to “Hold” at BidaskClub

Share on StockTwits

BioDelivery Sciences International (NASDAQ:BDSI) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Monday, BidAskClub reports.

A number of other analysts have also recently weighed in on BDSI. Cantor Fitzgerald set a $8.00 price target on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Friday, May 10th. Zacks Investment Research raised shares of BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $5.00 price target for the company in a research report on Tuesday, May 21st. Finally, ValuEngine cut shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. BioDelivery Sciences International has a consensus rating of “Buy” and an average target price of $6.20.

Shares of BioDelivery Sciences International stock opened at $4.40 on Monday. The business’s fifty day simple moving average is $4.11. The company has a current ratio of 2.88, a quick ratio of 2.57 and a debt-to-equity ratio of 1.90. BioDelivery Sciences International has a twelve month low of $2.55 and a twelve month high of $5.37. The stock has a market cap of $389.49 million, a PE ratio of -6.03 and a beta of 0.48.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.12. BioDelivery Sciences International had a negative net margin of 34.73% and a negative return on equity of 1.10%. The firm had revenue of $29.68 million during the quarter, compared to analysts’ expectations of $25.30 million. On average, analysts predict that BioDelivery Sciences International will post -0.15 earnings per share for the current year.

In other BioDelivery Sciences International news, Director Francis E. Odonnell, Jr. sold 8,000 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $4.68, for a total value of $37,440.00. Following the transaction, the director now owns 604,754 shares in the company, valued at approximately $2,830,248.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mark A. Sirgo sold 484,752 shares of the business’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $4.22, for a total transaction of $2,045,653.44. Following the completion of the transaction, the director now owns 2,559,803 shares in the company, valued at approximately $10,802,368.66. The disclosure for this sale can be found here. Insiders sold a total of 599,458 shares of company stock worth $2,546,413 in the last quarter. 8.94% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of BDSI. BlackRock Inc. lifted its holdings in BioDelivery Sciences International by 277.2% in the 2nd quarter. BlackRock Inc. now owns 5,498,457 shares of the specialty pharmaceutical company’s stock worth $25,568,000 after buying an additional 4,040,621 shares in the last quarter. Emerald Advisers LLC lifted its holdings in BioDelivery Sciences International by 881.4% in the 1st quarter. Emerald Advisers LLC now owns 1,734,422 shares of the specialty pharmaceutical company’s stock worth $9,192,000 after buying an additional 1,557,692 shares in the last quarter. Emerald Mutual Fund Advisers Trust raised its stake in shares of BioDelivery Sciences International by 836.4% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 1,556,947 shares of the specialty pharmaceutical company’s stock valued at $8,252,000 after purchasing an additional 1,390,682 shares in the last quarter. Stonepine Capital Management LLC raised its stake in shares of BioDelivery Sciences International by 79.6% in the 2nd quarter. Stonepine Capital Management LLC now owns 2,764,475 shares of the specialty pharmaceutical company’s stock valued at $12,855,000 after purchasing an additional 1,225,038 shares in the last quarter. Finally, Millennium Management LLC raised its stake in shares of BioDelivery Sciences International by 703.6% in the 4th quarter. Millennium Management LLC now owns 981,422 shares of the specialty pharmaceutical company’s stock valued at $3,631,000 after purchasing an additional 859,292 shares in the last quarter. Hedge funds and other institutional investors own 57.51% of the company’s stock.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Further Reading: Discover Your Risk Tolerance

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

CSat Investment Advisory L.P. Increases Stake in Humana Inc
CSat Investment Advisory L.P. Increases Stake in Humana Inc
CSat Investment Advisory L.P. Boosts Stake in PepsiCo, Inc.
CSat Investment Advisory L.P. Boosts Stake in PepsiCo, Inc.
CSat Investment Advisory L.P. Boosts Stake in Alibaba Group Holding Ltd
CSat Investment Advisory L.P. Boosts Stake in Alibaba Group Holding Ltd
CSat Investment Advisory L.P. Cuts Position in Nasdaq Inc
CSat Investment Advisory L.P. Cuts Position in Nasdaq Inc
CSat Investment Advisory L.P. Sells 621 Shares of General Mills, Inc.
CSat Investment Advisory L.P. Sells 621 Shares of General Mills, Inc.
Line Corp  Shares Sold by CSat Investment Advisory L.P.
Line Corp Shares Sold by CSat Investment Advisory L.P.


© 2006-2019 Ticker Report